News

Rituximab at fixed regimen better for long-term remission: Study

An 18-month fixed-schedule maintenance regimen of rituximab is better at keeping ANCA-associated vasculitis (AAV) in remission for up to seven years than azathioprine or a rituximab regimen tailored to an individual, according to pooled data from the Phase 3 MAINRITSAN program. Doubling the length of this fixed-schedule regimen did…

Phase 1 trial to open into SC291, CAR T-cell therapy for AAV

The U.S. Food and Drug Administration has approved Sana Biotechnology’s investigational new drug (IND) application requesting a Phase 1 clinical trial of its investigational cell therapy SC291 in people with ANCA-associated vasculitis (AAV) and other autoimmune diseases. “Our goal is to develop SC291 for patients with multiple…

AAV can lead to weak trunk muscles in very rare cases

In rare cases, ANCA-associated vasculitis (AAV) can result in muscle weakness that affects mainly the trunk and the muscles closest to the trunk due to blood vessel inflammation within the muscles, a study shows. Comprehensive tests of four AAV patients with this distinct clinical feature show that muscle symptoms…

Complement protein in blood may predict kidney damage in MPA

High blood levels of the immune protein C4 are significantly associated with greater kidney-specific disease activity and a higher chance of developing kidney failure with microscopic polyangiitis (MPA), the most common type of ANCA-associated vasculitis (AAV), a study shows. For this reason, measuring blood C4 levels may help predict…